JP6806342B2 - インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ - Google Patents

インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ Download PDF

Info

Publication number
JP6806342B2
JP6806342B2 JP2017552439A JP2017552439A JP6806342B2 JP 6806342 B2 JP6806342 B2 JP 6806342B2 JP 2017552439 A JP2017552439 A JP 2017552439A JP 2017552439 A JP2017552439 A JP 2017552439A JP 6806342 B2 JP6806342 B2 JP 6806342B2
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
cancer
mmol
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017552439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514518A (ja
JP2018514518A5 (https=
Inventor
ワン、ヘシャン
チャン、グオリャン
グオ、ユンハン
レン、ボ
ワン、ジウェイ
チョウ、チャンヨウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2018514518A publication Critical patent/JP2018514518A/ja
Publication of JP2018514518A5 publication Critical patent/JP2018514518A5/ja
Application granted granted Critical
Publication of JP6806342B2 publication Critical patent/JP6806342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017552439A 2015-04-10 2016-04-08 インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ Active JP6806342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076296 2015-04-10
CN2015076296 2015-04-10
PCT/CN2016/078787 WO2016161960A1 (en) 2015-04-10 2016-04-08 NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES

Publications (3)

Publication Number Publication Date
JP2018514518A JP2018514518A (ja) 2018-06-07
JP2018514518A5 JP2018514518A5 (https=) 2020-11-12
JP6806342B2 true JP6806342B2 (ja) 2021-01-06

Family

ID=57073074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017552439A Active JP6806342B2 (ja) 2015-04-10 2016-04-08 インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ

Country Status (7)

Country Link
US (2) US10280163B2 (https=)
EP (1) EP3280715B1 (https=)
JP (1) JP6806342B2 (https=)
KR (1) KR20170137165A (https=)
CN (2) CN107531693B (https=)
TW (1) TWI698435B (https=)
WO (1) WO2016161960A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI698435B (zh) 2015-04-10 2020-07-11 英屬開曼群島商百濟神州有限公司 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
WO2018036414A1 (zh) * 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 稠杂环类衍生物、其制备方法及其在医学上的应用
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
CA3047002A1 (en) * 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
TW201920202A (zh) 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
CN111051305A (zh) * 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
CN111601808B (zh) * 2017-10-19 2023-09-08 捷思英达医药技术（上海）有限公司 杂环化合物及其组合物和使用方法
KR20200074971A (ko) * 2017-10-19 2020-06-25 제이에스 이노팜 (상하이) 리미티드 헤테로사이클릭 화합물, 헤테로사이클릭 화합물을 포함하는 조성물 및 그의 사용 방법
CN107721915A (zh) * 2017-11-12 2018-02-23 刘磊 一种氯羟吡啶毒性杂质dcal的制备及纯化方法
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
ES2907282T3 (es) * 2018-01-15 2022-04-22 Idorsia Pharmaceuticals Ltd Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptófano dioxigenasa
CN110092750B (zh) 2018-01-29 2023-07-21 北京诺诚健华医药科技有限公司 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN109293588B (zh) * 2018-11-14 2022-02-01 四川大学 一种具有ido1/tdo双靶点的小分子化合物及其制备方法与应用
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP3997083A1 (en) * 2019-07-11 2022-05-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
TW202246259A (zh) 2021-01-29 2022-12-01 瑞士商赫孚孟拉羅股份公司 吡唑醯胺衍生物
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
WO2023133524A1 (en) * 2022-01-06 2023-07-13 Terran Biosciences, Inc. A process for synthesizing ketanserin
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
WO2025260150A1 (en) * 2024-06-21 2025-12-26 Microbiológica Química E Farmacêutica Ltda. Novel n-benzyl phthalimides for the treatment of pain. methods of preparation and therapeutic use
CN119707787B (zh) * 2024-12-24 2025-09-19 陕西师范大学 一种光连续流动合成4-烷基吡啶类化合物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2005086808A2 (en) 2004-03-08 2005-09-22 The University Of North Carolina At Chapel Hill NOVEL DICATIONIC IMIDAZO[1,2-a]PYRIDINES AND 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2a]PYRIDINES AS ANTIPROTOZOAL AGENTS
FR2906250B1 (fr) 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
JP5612860B2 (ja) 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
NO2694640T3 (https=) * 2011-04-15 2018-03-17
CN102532144B (zh) 2012-01-20 2014-09-10 辽宁思百得医药科技有限公司 一种新型吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
KR20150126623A (ko) 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
TWI698435B (zh) 2015-04-10 2020-07-11 英屬開曼群島商百濟神州有限公司 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
KR20190040502A (ko) 2016-08-26 2019-04-18 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑

Also Published As

Publication number Publication date
EP3280715A4 (en) 2019-03-13
TW201706270A (zh) 2017-02-16
TWI698435B (zh) 2020-07-11
JP2018514518A (ja) 2018-06-07
WO2016161960A1 (en) 2016-10-13
HK1244787A1 (zh) 2018-08-17
CN107531693B (zh) 2021-07-06
US20190284184A1 (en) 2019-09-19
EP3280715B1 (en) 2020-11-25
US10647714B2 (en) 2020-05-12
CN110872289A (zh) 2020-03-10
CN107531693A (zh) 2018-01-02
KR20170137165A (ko) 2017-12-12
US20180072716A1 (en) 2018-03-15
EP3280715A1 (en) 2018-02-14
US10280163B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
JP6806342B2 (ja) インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
JP7207629B2 (ja) Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物
JP6380862B2 (ja) 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
JP7014736B2 (ja) がんの処置のためのピラゾロピリジン誘導体
US7566716B2 (en) Imidazopyrazines as Raf inhibitor compounds
JP5868521B2 (ja) Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP6204568B2 (ja) タンパク質キナーゼ阻害剤としての縮合複素環化合物
JP6820254B2 (ja) 治療用化合物およびその使用
EP3697786B1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
JP5628902B2 (ja) フェノキシメチル複素環化合物
CN103282363B (zh) 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
JP2021515773A (ja) ＰＩ３Ｋ−γ阻害剤としてのアミノピラジンジオール化合物
US20260078103A1 (en) Isoquinolones as pi3k inhibitors
WO2020233676A1 (en) Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenases
HK40014846A (en) Novel 8-substituted imidazo[1, 5-a] pyridines as ido1 and/or tdo inhibitor
HK1244787B (zh) 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
JP6175519B2 (ja) Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
CN105348299B (zh) 作为raf激酶抑制剂的稠合三环化合物
HK1221222B (en) Fused tricyclic compounds as raf kinase inhibitors
HK1263053A1 (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
HK1192232B (en) Fused tricyclic compounds as raf kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201126

R150 Certificate of patent or registration of utility model

Ref document number: 6806342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360